CD34 and neoplasm: The immunological responses that have typically been evaluated during the course of tumor development or treatment include Th1 anti-tumor responses as well as immune inhibitory arms of immune reactivity that include Treg, Th2, and the less mature myeloid-derived suppressor cells or the related CD34+ progenitor cells [20,21,22,23,24,25,26].